Archive 1995–2023
2020, volume 36, issue 2
Original article
A randomized, double-blind, placebo-controlled study of polyunsaturated fatty acids efficacy in adolescents with anorexia nervosa
Agnieszka M. Piróg-Balcerzak, Anna K. Bażyńska, Katarzyna Biernacka, Joanna Brągoszewska, Lidia Popek, Barbara Remberk, Natalia Orlecka, Filip Rybakowski
Farmakoterapia w Psychiatrii i Neurologii 2020, 36 (2), 95–106
Original article
The assessment of psychopathological symptoms and the course of schizophrenia depending on gender, duration of the disease, somatic comorbidity and suicide attempts
Marta Broniarczyk-Czarniak, Agata Orzechowska, Piotr Gałecki
Farmakoterapia w Psychiatrii i Neurologii 2020, 36 (2), 107–115
Review article
Lurasidone – pharmacodynamic and pharmacokinetic properties, clinical potential and interaction risk
Marcin Siwek, Anna J. Krupa, Anna Wasik
Farmakoterapia w Psychiatrii i Neurologii 2020, 36 (2), 117–134
Review article
The role of blocking serotonin 2C receptor by fluoxetine in the treatment of bulimia
Marek Krzystanek, Artur Pałasz
Farmakoterapia w Psychiatrii i Neurologii 2020, 36 (2), 135–141
Case report
A severe course of the COVID-19 in a patient receiving prophylactically lithium
Karolina Gattner, Janusz Rybakowski
Farmakoterapia w Psychiatrii i Neurologii 2020, 36 (2), 143–148
Case report
New psychopharmacotherapy dilemmas associated with COVID-19 – case report
Jolanta Kucharska-Mazur, Jędrzej Stańczak, Jerzy Samochowiec
Farmakoterapia w Psychiatrii i Neurologii 2020, 36 (2), 149–153